Exactus, Inc. (EXDI)
Exactus, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Delray Beach, FL, US. The stock last traded at $0.07, down 10.96% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of -0.30, a net margin of -402.2%. Its beta of 4.32 implies it has historically moved more than the broad market.
Exactus, Inc. is a leading producer and supplier, specializing in ingredients derived from hemp as well as cutting-edge feminized hemp genetics. The company's offerings include feminized genetic strains rich in both cannabidiol (CBD) and high-cannabigerol (CBG). Beyond genetics, Exactus provides a comprehensive range of hemp-derived specialty ingredients, such as purified isolates of CBD, CBG, CBN, and CBC; potent CBD and CBG distillates; water-soluble CBD formulations; raw CBD and CBG biomass; dried CBD and CBG flowers; and CBD crude oil. They also offer white-label product solutions, serving a diverse clientele across the cosmetic, health and wellness, food and beverage, pharmaceutical, and pet care sectors. Exactus further extends its capabilities to custom manufacturing an assortment of cannabinoid-infused specialty products, including skincare items, pain relief creams, tinctures, bath bombs, soft gels, balms, pet-specific goods, and dietary supplements. The company's operations are based in Delray Beach, Florida, functioning as a subsidiary under Ceed2Med, LLC.
Exactus, Inc. is most often compared with the following Healthcare names: